Cytek Biosciences Inc
NASDAQ:CTKB
Gross Margin
Cytek Biosciences Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
498.6m USD |
54%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
957.9B USD |
56%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
181.3B USD |
41%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
139.5B USD |
60%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
53%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38B CHF |
33%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
308.6B CNY |
43%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
36.3B USD |
54%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
32.2B USD |
34%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.8B USD |
60%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18B EUR |
45%
|
Cytek Biosciences Inc
Glance View
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Cytek Biosciences Inc's most recent financial statements, the company has Gross Margin of 54.4%.
You don't have any saved screeners yet